Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2Seeking Alpha • 02/28/25
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 02/27/25
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of DirectorsGlobeNewsWire • 02/25/25
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025GlobeNewsWire • 02/20/25
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024GlobeNewsWire • 11/15/24
Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver HealthSeeking Alpha • 11/13/24
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial OfficerGlobeNewsWire • 11/11/24
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of ObesityGlobeNewsWire • 11/07/24
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024GlobeNewsWire • 11/04/24
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024GlobeNewsWire • 10/15/24
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual ConferenceGlobeNewsWire • 10/01/24
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)GlobeNewsWire • 09/30/24